Company Overview: RegeneRx Biopharmaceuticals

Industry News

27 Feb

RegeneRx Licensee Receives FDA Permission to Conduct a Phase 3 Trial of RGN-137 for Epidermolysis Bullosa in U.S.

ROCKVILLE, Md., Feb. 27, 2017 /PRNewswire/ — RegeneRx Biopharmaceuticals, Inc. (RGRX) (“the Company” or “RegeneRx”), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that its licensee for RGN-137, GtreeBNT Co., Ltd., received a positive response from the U.S. FDA for its Phase 3 clinical...

Read more

30 Nov

RegeneRx to Present at 9th Annual LD Micro Investor Conference

ROCKVILLE, Md., Nov. 30, 2016 /PRNewswire/ — RegeneRx Biopharmaceuticals, Inc. (RGRX) (“the Company” or “RegeneRx”), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that J.J. Finkelstein, President and Chief Executive Officer, will present a corporate overview at the 9th Annual LD Micro Investor Conference...

Read more

9 Nov

RegeneRx Announces First Patients Enrolled in Phase 3 U.S. Dry Eye Clinical Trial (ARISE-2 Trial) with RGN-259

ROCKVILLE, Md., Nov. 9, 2016 /PRNewswire/ — RegeneRx Biopharmaceuticals, Inc. (RGRX) (“the Company” or “RegeneRx”), a clinical-stage drug development company focused on tissue protection, repair and regeneration, announced today that the first patients have been enrolled in a Phase 3 clinical trial (ARISE-2 trial) with RGN-259 (Thymosin beta 4), its...

Read more

2 Nov

RegeneRx Receives Notice of Allowance for Patent for Tβ4 Eye Drop Formulation

ROCKVILLE, Md., Nov. 2, 2016 /PRNewswire/ — RegeneRx Biopharmaceuticals, Inc.(RGRX) (“the Company” or “RegeneRx”), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for a single unit dosage eye...

Read more

30 Sep

RegeneRx Joint Venture Initiates Second Phase 3 Study Of RGN-259 for Dry Eye Syndrome

ROCKVILLE, Md., Sept. 30, 2016 /PRNewswire/ — RegeneRx Biopharmaceuticals, Inc. (RGRX) (“the Company” or “RegeneRx”), a clinical-stage drug development company focused on tissue protection, repair and regeneration, announced today that ReGenTree, RegeneRx’s U.S. joint venture with GtreeBNT, initiated its second Phase 3 trial for Dry Eye Syndrome this month...

Read more

30 Aug

RegeneRx to Present at Rodman & Renshaw 18th Annual Global Investment Conference

ROCKVILLE, Md., Aug. 30, 2016 /PRNewswire/ — RegeneRx Biopharmaceuticals, Inc. (RGRX) (“the Company” or “RegeneRx”), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that J.J. Finkelstein, President and Chief Executive Officer, will present a corporate overview at the Rodman & Renshaw 18th Annual Global...

Read more

24 Aug

RegeneRx Joint Venture to Begin Second Phase 3 Study Of RGN-259 for Dry Eye Syndrome in 3rd Quarter

ROCKVILLE, Md., Aug. 24, 2016 /PRNewswire/ — RegeneRx Biopharmaceuticals, Inc. (RGRX) (“the Company” or “RegeneRx”), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that its U.S. joint venture, ReGenTree, LLC, has received permission from the U.S. FDA to proceed with a second Phase 3 clinical trial...

Read more

3 Aug

RegeneRx Receives Notice of Allowance for Key U.S. Patent That Expands and Extends Exclusivity of Company’s Product Candidates

ROCKVILLE, Md., Aug. 3, 2016 /PRNewswire/ — RegeneRx Biopharmaceuticals, Inc.(RGRX) (“the Company” or “RegeneRx”), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for a Method of Achieving a...

Read more

Page 1 of 41234

Enter your email address to receive notifications of new posts by email.

Latest Tweets

Follow

Follow this blog

Get every new post delivered right to your inbox.

Email address